Rafael Rosell
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Pangaea Oncology, Dexeus University Hospital: bridging preclinical and clinical research.
Journal: Molecular cancer
Published: January 24, 2024
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab.
Journal: Nature reviews. Clinical oncology
Published: December 06, 2023
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
Journal: Cell communication and signaling : CCS
Published: December 04, 2023
Promising outlook with sugemalimab in non-small-cell lung cancer.
Journal: The Lancet. Oncology
Published: November 15, 2021
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 15, 2021
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.
Journal: British journal of cancer
Published: May 05, 2021
Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Journal: Pharmacological research
Published: March 04, 2021
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 20, 2020
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 25, 2020
Last Updated: 09/26/2026